Prosecution Insights
Prosecution Insights
Listed by the USPTO as OH, TAYLOR V
Tech Center 1600 • Art Units: 1622 1624 1625 1629
This examiner grants 81% of resolved cases
Taylor V. Oh is an examiner in Tech Center 1600 and Art Unit 1622. She has 1776 resolved cases. Her allowance rate is 81.2 percent, and the median days to allowance is 825. The data shows an interview lift of 15.4 percent, suggesting that interviews are associated with a higher probability of allowance relative to the 81.2 percent baseline. This indicates that direct communication is a useful tool for applicants.
Top companies in her docket include LG Chem Ltd., Zydus Lifesciences Limited, and Syngenta AG. Firms such as Cooley LLP and Goodwin Procter LLP are frequently involved. The 81.2 percent allowance rate and 15.4 percent interview lift are based on a large sample of 1776 resolved cases. Practitioners should consider the 825 median days to allowance when planning their prosecution strategy and estimating the time to a final disposition. These metrics offer a comprehensive view of the examiner's efficiency.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18860397 | PROCESS FOR THE PREPARATION OF [1,4,5]-OXADIAZEPINE DERIVATIVES | Non-Final OA | Syngenta Crop Protection AG |
| 18832446 | THERAPEUTIC AGENT FOR CANCER | Non-Final OA | TOHOKU UNIVERSITY |
| 18792715 | Synthesis of MEK7 Inhibitors and methods of Use Thereof | Non-Final OA | Northwestern University |
| 18041627 | Methods and Compositions for Inhibiting Viral Infection | Non-Final OA | New York University |
| 18832887 | SYNTHESIS OF A KIF18A INHIBITOR | Non-Final OA | Amgen Inc. |
| 18811575 | PHOSPHONIUM-BEARING CONJUGATED POLYELECTROLYTES | Non-Final OA | Board of Regents, The University of Texas System |
| 18262256 | USES OF MELANOCORTIN-4 RECEPTOR AGONIST | Final Rejection | LG CHEM, LTD. |
| 18269168 | COMPOSITIONS AND METHODS RELATED TO BICYCLO[2.2.1] HEPTANAMINE-CONTAINING COMPOUNDS | Final Rejection | The Brigham and Women's Hospital, Inc. |
| 18850267 | ASCORBIC ACID DERIVATIVE OR SALT THEREOF, ADDITIVE FOR POLYMERIZATION INITIATION, POLYMERIZATION INITIATOR, CURABLE COMPOSITION PREPARATION KIT, CURABLE COMPOSITION, CURED PRODUCT, AND DENTAL MATERIAL | Non-Final OA | MITSUI CHEMICALS, INC. |
| 18294510 | A PHARMACEUTICAL COMBINATION AND USE THEREOF | Non-Final OA | Ascentage Pharma Group Corp Limited |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy81.2% of resolved applications examined by Taylor V Oh were allowed (1,776 resolved cases), compared with 60.7% across Art Unit 1622 over the last five years.
This examiner's interview lift is +15.4 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Taylor V Oh took 825 days on average from filing to allowance.
Taylor V Oh examines applications in Art Unit 1622 in Tech Center 1600 (Biotechnology & Pharmaceuticals).